Brilliant Violet 421™ anti-mouse Ly-6C Antib
- 产品名称：
- Brilliant Violet 421™ anti-mouse Ly-6C Antib
- 产品类别：
- 抗体
- 产品编号：
- 128031
- 产品应用：
- 128031
- Verified Reactivity
- Mouse
- Antibody Type
- Monoclonal
- Host Species
- Rat
- Immunogen
- L3 cloned CTL cells
- Formulation
- Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
- Preparation
- The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421? under optimal conditions.
- Concentration
- Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
- Application
-
FC - Quality tested
- Recommended Usage
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood. It is recommended that the reagent be titrated for optimal performance for each application. Brilliant Violet 421? excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421? is a trademark of Sirigen Group Ltd.
Learn more about Brilliant Violet?.
This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents. - Excitation Laser
- Violet Laser (405 nm)
- Application Notes
Clone HK1.4 does not block the binding of clone RB6-8C58.
Additional reported applications (for relevant formats of this clone) include: in vitro activation of T cells1-3 and immunohistochemistry of frozen sections4.
- Application References
(PubMed link indicates BioLegend citation) -
- Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819. (Activ)
- Herold KC, et al. 1990. Diabetes 39:815. (Activ)
- Havran WL, et al. 1988. J. Immunol. 140:1034 (Activ)
- Flanagan K, et al. 2008. J. Immunol. 180:3874. (IHC)
- Makaroff LE, et al. 2009. P. Natl. Acad. Sci. USA 106:4799. (FC)
- Zuber J, et al. 2009. Genes Dev. 23:877. (FC) PubMed
- Ribechini E, et al. 2009. Eur. J. Immunol. 39:3538.
- Ma C, et al. 2012. J. Leukoc. Biol. 92:1199.
- Watson NB, et al. 2015. J Immunol. 194:2796. PubMed
- Product Citations
-
- Platt DJ, et al. 2021. Cell Reports. 35(6):109113. PubMed
- Alissafi T, et al. 2018. J Clin Invest. 128:3840. PubMed
- Rogic A, et al. 2021. Nat Commun. 12:6889. PubMed
- Barberio AE, et al. 2020. ACS Nano. 14:11238. PubMed
- Harel M, et al. 2020. Cell. 179(1):236-250.e18.. PubMed
- Bagayoko S, et al. 2021. PLoS Pathog. 17:e1009927. PubMed
- Jassinskaja M, et al. 2021. Cell Reports. 34(12):108894. PubMed
- Tomlinson KL, et al. 2021. Nat Commun. 12:1399. PubMed
- Lu CY, et al. 2020. J Neurosci. 40:9602. PubMed
- Riquelme SA, et al. 2020. Cell Metabolism. 31(6):1091-1106.e6. PubMed
- Lian J, et al. 2020. Cell Reports. 31(8):107679. PubMed
- Hepler C et al. 2018. eLife. 7 pii: e39636. PubMed
- Germundson DL, et al. 2022. Front Allergy. 3:870513. PubMed
- Casulli J, et al. 2019. Nat Commun. 10:2121. PubMed
- Guichard V, et al. 2017. Elife. 6:e27215. PubMed
- Taylor D, et al. 2022. Front Immunol. 13:936129. PubMed
- Nahrendorf W, et al. 2021. eLife. 10:00. PubMed
- Kalafati L, et al. 2020. Cell. 183:771. PubMed
- Zhang Q, et al. 2015. Sci Rep. 5:15948. PubMed
- Bennett FC, et al. 2018. Neuron. 98:1170. PubMed
- Buffolo M, et al. 2019. Cell Rep. 29:270. PubMed
- Mello AM, et al. 2022. Oncogenesis. 11:56. PubMed
- Zheng Y, et al. 2022. J Immunol. 208:501. PubMed
- Willemsen J, et al. 2021. Cell Rep. 37:109977. PubMed
- Levy N, et al. 2015. J Immunol. 195: 1713-1722. PubMed
- Molgora M, et al. 2020. Cell. 182:886. PubMed
- Yoshida H, et al. 2019. Cell. 176:897. PubMed
- Tao Z, et al. 2022. Cells. 11:. PubMed
- Maller O, et al. 2020. Nat Mater. 20:548. PubMed
- Martins R, et al. 2016. Nat Immunol. 17:1361-1372. PubMed
- Calvente CJ, et al. 2019. J Clin Invest. 130:4091. PubMed
- Phadke MS, et al. 2021. Cancer Immunol Res. 9:554. PubMed
- Wang J, et al. 2020. Cell. 183(7):1867-1883.e26. PubMed
- Kilgore AM, et al. 2020. J Immunol. 204:510. PubMed
- Park CJ, et al. 2020. Cell Reports. 31(2):107496.. PubMed
- RRID
- AB_2562177 (BioLegend Cat. No. 128031) AB_2562178 (BioLegend Cat. No. 128032)
- Structure
- 14-17 kD protein (134 amino acids), member of the Ly-6 family of GPI linked protein. Ly6 family members share structure homology throughout a distinctive cystein rich protein domain that incorporates O-linked carbohydrates.
- Distribution
-
Ly-6C is expressed primarily on bone marrow myeloid populations, monocytes/macrophages, neutrophils, endothelial cells, and some T cell subsets. Ly-6C is also a marker of memory CD8+ T cells.
- Cell Type
- Endothelial cells, Macrophages, Monocytes, Neutrophils, T cells
- Biology Area
- Immunology
- Molecular Family
- CD Molecules
- Antigen References
-
1. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819.
2. Cerwenka A, et al. 1998. J. Immunol. 161:97.
- Gene ID
- 17067 View all products for this Gene ID
- UniProt
- View information about Ly-6C on UniProt.org
